Clinical Trial Results:
A Phase III, Randomized, Open-Label Study Investigating the Addition of Durvalumab to an Anthracycline-Taxane based Chemotherapy in Early-Stage Triple-Negative Breast Cancer
Summary
|
|
EudraCT number |
2018-001155-13 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
18 Mar 2022
|
First version publication date |
18 Mar 2022
|
Other versions |
|
Summary report(s) |
No-Results statement |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.